Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2012

View Archived Issues

Verva reports on proof-of-concept trial of repurposed drug

Spanish scientists discover new integrin antagonists

Janssen Pharmaceuticals presents novel mGlu2 receptor modulators

Actelion Pharmaceuticals synthesizes novel orexin receptor antagonists

Novel mineralocorticoid receptor antagonists presented

Janssen and Medivir develop novel agents for hepatitis

Gene therapy for choroideremia enters clinic

AstraZeneca TLR7 agonist assessed in four clinical trials

AX-01128 protects kidney transplant function in vivo

Researchers at the CNRS disclose novel inhibitors of tubulin polymerization

Amorfix licenses diagnostic test for Alzheimer's disease to JSW Life Sciences

FDA grants fast track designation to NKTR-181

Takeda transfers TAK-070 to university

Arrowhead Research prepares to file IND

FDA approves Horizant for new indication

Alnylam completes enrollment in phase I ALN-TTR02 study and begins phase II trial

Astellas makes first Dificlir sales in Europe, triggering milestone payment to Optimer

Trovagene and Strand Life Sciences enter collaboration in India and South Asia

U.K.'s NICE issues preliminary opinion on cost-effectiveness of Bronchitol for cystic fibrosis

Ongoing EULAR conference features long-term adalimumab efficacy data in spondylarthritis

FDA extends regulatory review period for ultralong-acting insulins

Sorrento Therapeutics receives new NIH grant

Mesoblast outlines plans to develop stem cell therapies for neurodegenerative diseases

AR-42 gets E.U. orphan drug status for two additional indications

Researchers describe novel monovalent CD28-targeted Fab' antibody fragment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...